Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Mahmoud Tareq Abdelwahab"'
Autor:
Juan Eduardo Resendiz-Galvan, Prerna R. Arora, Mahmoud Tareq Abdelwahab, Zarir F. Udwadia, Camilla Rodrigues, Amita Gupta, Paolo Denti, Tester F. Ashavaid, Jeffrey A. Tornheim
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2023)
Linezolid is an oxazolidinone used to treat multidrug-resistant tuberculosis (MDR-TB), including in the recently-endorsed shorter 6-month treatment regimens. Due to its narrow therapeutic index, linezolid is often either dose-adjusted or discontinued
Externí odkaz:
https://doaj.org/article/ada9e38b375c4575a3c14663f16b5161
Autor:
Noha Abdelgawad, Sean Wasserman, Mahmoud Tareq Abdelwahab, Angharad Davis, Cari Stek, Lubbe Wiesner, John Black, Graeme Meintjes, Robert J. Wilkinson, Paolo Denti
Publikováno v:
medRxiv
BackgroundLinezolid is being evaluated in novel treatment regimens for tuberculous meningitis (TBM). The pharmacokinetics of linezolid have not been characterized in this population, particularly in cerebrospinal fluid (CSF) where exposures may be af
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dee4cf72a56359bc20937908c1767ca
https://doi.org/10.1101/2023.04.06.23288230
https://doi.org/10.1101/2023.04.06.23288230
Autor:
Tjokosela Tikiso, Helen McIlleron, Mahmoud Tareq Abdelwahab, Adrie Bekker, Anneke Hesseling, Chishala Chabala, Geraint Davies, Heather J Zar, Helena Rabie, Isabelle Andrieux-Meyer, Janice Lee, Lubbe Wiesner, Mark F Cotton, Paolo Denti
Publikováno v:
J Antimicrob Chemother
Objectives Ethambutol protects against the development of resistance to co-administered drugs in the intensive phase of first-line anti-TB treatment in children. It is especially relevant in settings with a high prevalence of HIV or isoniazid resista
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4039111c9682cfb07f86289273dd6977
https://europepmc.org/articles/PMC9633720/
https://europepmc.org/articles/PMC9633720/
Autor:
David W Haas, Mahmoud Tareq Abdelwahab, Stijn W van Beek, Paxton Baker, Gary Maartens, Yuki Bradford, Marylyn D Ritchie, Sean Wasserman, Graeme Meintjes, Karen Beeri, Neel R Gandhi, Elin M Svensson, Paolo Denti, James C M Brust
Publikováno v:
The Journal of Infectious Diseases, 226, 1, pp. 147-156
The Journal of Infectious Diseases, 226, 147-156
J Infect Dis
The Journal of Infectious Diseases, 226, 147-156
J Infect Dis
Background Plasma bedaquiline clearance is reportedly more rapid with African ancestry. Our objective was to determine whether genetic polymorphisms explained between-individual variability in plasma clearance of bedaquiline, its M2 metabolite, and c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87c21f215619d7d4fbea10d8ca7771e0
https://repository.ubn.ru.nl/handle/2066/283102
https://repository.ubn.ru.nl/handle/2066/283102
Autor:
Gary Maartens, Keertan Dheda, Lubbe Wiesner, Frederick A. Sirgel, Neel R. Gandhi, Sean Wasserman, James C.M. Brust, Graeme Meintjes, Mahmoud Tareq Abdelwahab, Paolo Denti, Robin M. Warren
Publikováno v:
Antimicrob Agents Chemother
Linezolid is widely used for drug-resistant tuberculosis (DR-TB) but has a narrow therapeutic index. To inform dose optimization, we aimed to characterize the population pharmacokinetics of linezolid in South African participants with DR-TB and explo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16948bfefeea549912051e8fe5a28ff1
https://europepmc.org/articles/PMC8597769/
https://europepmc.org/articles/PMC8597769/
Autor:
Mahmoud Tareq Abdelwahab, Gary Maartens, Daniel Everitt, Paolo Denti, Richard Court, Rodney Dawson, Andreas H. Diacon, Elin M. Svensson
Publikováno v:
Antimicrobial Agents and Chemotherapy, 65, 7
Antimicrobial Agents and Chemotherapy, 65
Antimicrob Agents Chemother
Antimicrobial Agents and Chemotherapy, 65
Antimicrob Agents Chemother
Contains fulltext : 235750.pdf (Publisher’s version ) (Closed access) Clofazimine is classified as a WHO group B drug for the treatment of rifampin-resistant tuberculosis. QT prolongation, which is associated with fatal cardiac arrhythmias, is caus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47072d81e97f4d7f9e09b44a8f7d265f
https://repository.ubn.ru.nl/handle/2066/235750
https://repository.ubn.ru.nl/handle/2066/235750
Autor:
Grace L. Barnes, Paolo Denti, Kelly E. Dooley, Mahmoud Tareq Abdelwahab, Elisa H. Ignatius, Lubbe Wiesner, Nikhil Gupte, Bronwyn Hendricks, Rodney Dawson, Kim Narunsky
Publikováno v:
Antimicrob Agents Chemother
Shorter, more potent regimens are needed for tuberculosis. The nitroimidazole pretomanid was recently approved for extensively drug-resistant tuberculosis in combination with bedaquiline and linezolid. Pretomanid may also have benefit as a treatment-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37275d067b58dac3249fb9a8954808cb
https://pubmed.ncbi.nlm.nih.gov/33229425
https://pubmed.ncbi.nlm.nih.gov/33229425
Autor:
Rodney Dawson, James C.M. Brust, Daniel Everitt, Paolo Denti, Elin M. Svensson, Andreas H. Diacon, Lubbe Wiesner, Gary Maartens, Graeme Meintjes, Mahmoud Tareq Abdelwahab, Sean Wasserman, Neel R. Gandhi
Publikováno v:
Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy, 75, 3269-3277
Journal of Antimicrobial Chemotherapy, 75, 11, pp. 3269-3277
Journal of Antimicrobial Chemotherapy, 75, 3269-3277
Journal of Antimicrobial Chemotherapy, 75, 11, pp. 3269-3277
Background Clofazimine is in widespread use as a key component of drug-resistant TB regimens, but the recommended dose is not evidence based. Pharmacokinetic data from relevant patient populations are needed to inform dose optimization. Objectives To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd29aa434079debef7d3823d3848e1e2
https://pubmed.ncbi.nlm.nih.gov/32747933
https://pubmed.ncbi.nlm.nih.gov/32747933
Autor:
Matebogo Letutu, Kelly E. Dooley, Ziyaad Waja, Lubbe Wiesner, Paolo Denti, Rory Leisegang, Helen McIlleron, Jyoti S. Mathad, Neil A. Martinson, Mahmoud Tareq Abdelwahab, Richard E. Chaisson
Publikováno v:
Antimicrob Agents Chemother
Tuberculosis is an important cause of maternal morbidity, but little is known about the effects of pregnancy on antituberculosis drug concentrations. We developed population pharmacokinetic models to describe drug dispositions of isoniazid, pyrazinam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c977a8cfe71573120d68d20da1542774
https://doi.org/10.1128/aac.01978-19
https://doi.org/10.1128/aac.01978-19